Latest Breaking News On - குமார் பிரபாஷ் - Page 1 : comparemela.com

Study: Lung squamous patients harboring druggable mutations have lower median overall survival Oncotarget published Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations which reported that unlike lung adenocarcinoma patients, there is no FDA-approved targeted-therapy likely to benefit lung squamous cell carcinoma patients. The authors performed survival analyses of lung squamous cell carcinoma patients harboring therapeutically relevant alterations identified by whole exome sequencing and mass spectrometry-based validation across 430 lung squamous tumors. They report a mean of 11.6 mutations/Mb with a characteristic smoking signature along with mutations in TP53, CDKN2A, NFE2L2, FAT1, KMT2C, LRP1B, FGFR1, PTEN and PREX2 among lung squamous cell carcinoma patients of Indian descent.

Amit duttKumar prabhashEmily hendersonOncotarget research outputDutt prabhash research teamPrabhash research teamSquamous cell carcinomaExome sequencingLung cancerMass spectrometryஅமித் தத்குமார் பிரபாஷ்எமிலி ஹென்டர்சன்பிரபாஷ் ஆராய்ச்சி அணி